Business Wire

Novodiag® Bacterial GE+, a New Diagnostic Test for on-Demand Detection of Bacterial Pathogens

Jaa

Mobidiag, a Finnish molecular diagnostics company, today announced the launch of Novodiag® Bacterial GE+, a molecular diagnostic test for the simultaneous detection of most common enteric pathogens directly from stool samples. Compatible with the fully automated Novodiag® system launched at the end of 2017, this new disposable cartridge allows direct analysis of a patient sample and delivers comprehensive results in about an hour, compared to days with currently used culture methods.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180416005997/en/

Novodiag® Bacterial GE+, molecular diagnostic test for on-demand detection of bacterial pathogens (P ...

Novodiag® Bacterial GE+, molecular diagnostic test for on-demand detection of bacterial pathogens (Photo: Mobidiag)

“The new Novodiag Bacterial GE+ cartridge can identify dozens of targets, including the majority of bacteria causing diarrhea. Thanks to its simplified and optimized workflow, our fully automated Novodiag solution can support early decision making prior to any treatment delivery and improve patient care by managing infections accordingly” explains Tuomas Tenkanen. “We are very proud to now offer the first syndromic test compatible with our Novodiag system. Our ambition is to make accessible one of the most relevant range of test panels. We are currently working on extending our product line and address among others the detection of antibiotic resistances to improve the correct use of antibiotics”.

Novodiag® Bacterial GE+ test is now available directly through Mobidiag and local distributors. For more information, visit our product page.

About Novodiag ® (CE-IVD)
The Novodiag solution allows direct analysis of a patient sample placed in a disposable cartridge and delivers comprehensive results in about an hour. Combining qPCR and microarray technologies, Novodiag offers an all in one solution for on-demand targeted and syndromic testing.
This molecular diagnostic solution offers an easy to use and cost-efficient method, with very limited hands-on-time and without the need for much technical expertise. Novodiag is suitable for all test volumes and on demand testing for clinical laboratories.
Learn more about Novodiag.

About Mobidiag Ltd.
Established in 2000, Mobidiag develops and commercializes innovative solutions to advance the diagnosis of infectious diseases and serves the European clinical diagnostics market since 2008. Mobidiag is headquartered in Espoo, Finland, with an R&D center in France and subsidiaries in UK and Sweden.
Combining Amplidiag and Novodiag solutions, Mobidiag offers a comprehensive line of products for fast, reliable and cost-efficient diagnostics for infectious diseases and antibiotic resistances. Mobidiag is able to cover all laboratories requirements no matter their size, throughput and centralized/ decentralized organization.
To learn more, visit mobidiag.com

Contact information

Mobidiag
Dorothee Allard, +33 1 55 25 17 13
marketing@mobidiag.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

NEC Iris Recognition Technology Ranks First in NIST Accuracy Testing27.4.2018 05:00Tiedote

NEC Corporation (NEC) (TOKYO: 6701) today announced that its iris recognition technology achieved the highest matching accuracy evaluation in the recent Iris Exchange (IREX,*1) IX evaluations of automated iris recognition algorithms performed by the U.S. National Institute of Standards and Technology (NIST). Iris recognition technology is a biometrics identifier that uses patterns from the iris, the donut-like tissue that surrounds the pupil. In recent years, this technology has been adopted by systems that require large-scale matching, mainly for organizations and companies, since it is possible to quickly provide highly accurate authentication with devices that do not require physical contact. From the standpoint of privacy protection and security enhancement, government agencies in particular are in growing need of reliable personal authentication for purposes that include citizen ID, immigration control and criminal investigations. NEC received the top accuracy ranking in the IREX

Gemalto First Quarter 2018 Revenue27.4.2018 01:00Tiedote

Regulatory News: Gemalto (Euronext NL0000400653 - GTO), the world leader in digital security today announces its revenue for the first quarter of 2018. Revenue (€ in millions) First quarter 2018 First quarter 2017 Change at constant exchange rates Change at historical exchange rates Identity, IoT & Cybersecurity 293 256 +24% +15% Smartcards & Issuance 357 396 (2%) (10%) Total 650 651 +8% = Philippe Vallée, Chief Executive Officer, commented: “Gemalto grew well this quarter driven by a solid increase in the Identity, IoT & Cybersecurity segment that more than offset the anticipated revenue decrease in the Smartcards & Issuance segment. During the quarter, commercial synergies with the newly acquired Identity Management business began to kick in and resulted in milestone wins in Governments. Gemalto also announced the launch of two ground-breaking laser-personalized innovations designed to significantly increase the security of passports and IDs. The Cybersecurity business grew well in E

Elliott Advisors (UK) Limited Statement on Telecom Italia26.4.2018 22:49Tiedote

Elliott Advisors (UK) Limited (“Elliott”) today sent a new letter and a presentation to Telecom Italia (“TIM” or the “Company”) shareholders calling upon shareholders to uphold best practice governance principles at TIM’s upcoming shareholder meeting on May 4th. Inadequate governance and poor stewardship have imposed a heavy cost on TIM’s stakeholders for too long. Vivendi’s repeated missteps and self-serving behaviour have eroded the value of TIM’s shares and destroyed shareholder trust. The question being put to TIM shareholders on May 4th is: can you entrust your investment to Vivendi as long-term stewards of your capital and this company moving forward? Shareholders should take the opportunity to correct a governance structure rife with conflict and demand high quality and independent stewardship at the Board level. Shareholders have the opportunity to remove an otherwise permanent, persisting and pervasive impairment of value. This pivotal vote offers a textbook opportunity to put

Javier Gómez Noya Chooses ROKA Eyewear26.4.2018 21:15Tiedote

ROKA, the Austin-based performance design company, has announced a multiyear eyewear partnership with eight-time triathlon world champion and Olympic silver medalist Javier Gómez Noya, expanding their existing relationship for technical race apparel and equipment. Starting in 2018, Gómez will train and race in ROKA’s eyewear, the lightest, most advanced performance optics in the world, in the pursuit of his first Ironman World Championship. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180426006510/en/ Javier Gómez Noya Chooses ROKA Eyewear (Photo: Business Wire) “I first tried the Advanced Performance eyewear while I was at ROKA’s headquarters in Texas, and right away I knew they were the glasses I should be using everyday,” Gómez Noya says. “There’s nothing like them in terms of weight, retention, and quality of vision. Whether cycling or running, you can’t feel that you’re wearing them but you have an incredible field of

Egyptian Singer Becomes First Woman to Perform Before a Mixed Crowd in Saudi Arabia26.4.2018 20:55Tiedote

History was made in Saudi Arabia on Wednesday as a female singer performed before a mixed audience for the first time in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180426006471/en/ Egypt’s National Arab Music Ensemble of the Egyptian Opera House debuted in Saudi Arabia with the singer Nihad Fathy performing before a 2,500-strong audience in Riyadh. This is the first time a woman singer performed on stage in the Kingdom before a mixed crowd. (Photo courtesy of GCA Saudi Arabia.) Egypt’s National Arab Music Ensemble (AME) of the Egyptian Opera House debuted in the Kingdom with the singer Nihad Fathy performing before a 2,500-strong audience at King Fahad Cultural Center in Riyadh. The crowd broke into a rapturous applause as she took to the stage. The Egyptian Opera House ensemble, which was led by famous conductor Moustafa Helmy, comprised 45 male and female musicians and singers, including the star singers A

Pharnext Appoints Amit Kohli as Chief Operating Officer26.4.2018 19:00Tiedote

Regulatory News: Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big genomic data and artificial intelligence, today announced the appointment of Amit Kohli, a senior healthcare industry executive, as Chief Operating Officer (COO). Mr. Kohli is responsible for leading Pharnext’s corporate strategy and operations. “Amit is a seasoned leader with over 20 years’ experience in the healthcare industry, and we are thrilled he is joining Pharnext,” said Prof. Daniel Cohen, M.D., Ph.D., Co-Founder and Chief Executive Officer of Pharnext. “We are deeply impressed with Amit’s results-oriented track record, and his ability to drive business strategy and operations across the pharma, medtech and clinical diagnostics sectors. We believe Pharnext will greatly benefit from his extensive cross-functional leadership experience especially as our first-in-class orphan drug, PXT3003, for the

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme